Loading
A phase 2 trial in colorectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, now recruiting.
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE） is a phase 2, interventional study registered as NCT06767007 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 31 participants, started 2025-01-06 and due to reach its primary completion in 2026-11-30. Interventions recorded: Stereotactic Body Radiation Therapy (SBRT); PD1; Chemotherapy. Conditions listed: Unresectable Locally Recurrent Rectal Cancer. Primary outcome: 1 year PFS. Colorectal eligibility wording from the registry: "Patients with pMMR/MSS colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.